Mannkind Corporation (NASDAQ:MNKD) shares surged by more than 9% today after analysts praised the company’s insulin drug Afrezza.
Mannkind dropped 12% yesterday after it was revealed a competitor, Biodel Inc. (NASDAQ:BIOD) , was moving along with other insulin medications for treatment of diabetes.
Today analyst Keith Markey of Griffin Securities said , “We think the selloff was a mistake — Afrezza is the better drug,”
As a result Mannkind Corporation (NASDAQ:MNKD) shares are up today nearly 8% as it tries to regain yesterdays losses. Meanwhile Biodel Inc (NASDAQ:BIOD) gave back all it gains from yesterday
About Mannkind Corporation
Mannkind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetics and cancer.
Latest posts by Karen Jackson (see all)
- Intoxicated South Carolina Man Punches Waitress Who Refused to Serve Him Alcohol - November 23, 2020
- Restaurant Manager Arrested and Charged in Shooting Death of Co-Worker over Negative Yelp Reviews - November 23, 2020
- Minnesota Teen Gets Head Stuck In Oversized Tailpipe Winstock Music Festival - November 23, 2020